Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:05 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 838 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: EGFR Clear all

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 317 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic or Recurrent Squamous Cell Carcinoma of the Esophagus
Interventions: Lapatinib; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Advanced Non Small Cell Lung Cancer, Failed Prior Chemotherapy
Interventions: Tarceva (Trademark) (erlotinib HCl, OSI-774); Drug
Lead sponsor: OSI Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Colorectal Cancer
Interventions: Panitumumab and bortezomib; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Breast Cancer
Interventions: Abemaciclib, Letrozole; Drug
Lead sponsor: Mridula George, MD; Other
Eligibility: 60 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 4
States / cities: Belleville, New Jersey • Livingston, New Jersey • New Brunswick, New Jersey + 1 more

Conditions: HEAD & NECK Cancer
Interventions: Cetuximab, IMRT, Albumin-bound paclitaxel (Abraxane®); Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 100 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 5
States / cities: Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more

Conditions: Locally Advanced or Metastatic Non Small Cell Lung Cancer
Interventions: Rociletinib; Drug
Lead sponsor: Clovis Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 612 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 39
States / cities: Duarte, California • Fountain Valley, California • Los Angeles, California + 32 more

Conditions: Glioblastoma, Astrocytoma, Grade IV
Interventions: EGFR(V)-EDV-Dox; Drug
Lead sponsor: Engeneic Pty Limited; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 2
States / cities: Baltimore, Maryland • New York, New York

Conditions: Non-Small Cell Lung Cancer
Interventions: Sunvozertinib; Drug
Lead sponsor: Dizal Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 12
States / cities: La Jolla, California • Orange, California • Whittier, California + 8 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Ivonescimab, Dato-DXd, Osimertinib; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: EGFR NP_005219.2:p.S492R, KRAS Gene Mutation, MAP2K1 Gene Mutation, Metastatic Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
Interventions: Laboratory Biomarker Analysis, Panitumumab, Trametinib; Other · Biological · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: gefitinib, Surgery; Drug · Procedure
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 35 Years and older · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 2
States / cities: Nashville, Tennessee

Conditions: Coronary Artery Stenosis
Interventions: Non ionic contrast media comparator; Drug
Lead sponsor: Bracco Diagnostics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Springfield, Illinois

Conditions: Breast Cancer
Interventions: Vepdegestrant, Palbociclib; Drug
Lead sponsor: Arvinas Estrogen Receptor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 16
States / cities: Palo Alto, California • San Francisco, California • Santa Monica, California + 12 more

Conditions: Non-small Cell Lung Cancer
Interventions: Erlotinib, Placebo; Drug
Lead sponsor: OSI Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1,252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 149
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 122 more

Conditions: Neoplasms, Neoplasm Metastasis
Interventions: LY3164530; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 3
States / cities: Scottsdale, Arizona • Houston, Texas • San Antonio, Texas

Conditions: Colorectal Neoplasms, Metastases, Neoplasm
Interventions: Erbitux (Cetuximab); Biological
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Non-small Cell Lung Cancer
Interventions: H002; Drug
Lead sponsor: RedCloud Bio; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 4
States / cities: Los Angeles, California • Boston, Massachusetts • New York, New York + 1 more

Conditions: Metastatic Colorectal Cancer
Interventions: Panitumumab, Irinotecan; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 8
States / cities: Billings, Montana • Chapel Hill, North Carolina • Philadelphia, Pennsylvania + 1 more

Conditions: Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer
Interventions: Lurbinectedin, Osimertinib; Drug
Lead sponsor: Misty Shields; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Non Small Cell Lung Cancer Metastatic
Interventions: osimertinib, stereotactic radiosurgery (SRS); Drug · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 8
States / cities: Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more

Conditions: NSCLC (Advanced Non-small Cell Lung Cancer)
Interventions: BH-30643, BH-30643 combo therapy with Carboplatin/Pemetrexed; Drug
Lead sponsor: BlossomHill Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 675 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 25
States / cities: Phoenix, Arizona • Irvine, California • La Jolla, California + 19 more

Conditions: Advanced Solid Tumors, Colorectal Cancer, Squamous Cell Head and Neck Cancer, Non Small Cell Lung Cancer, Triple Negative Breast Cancer
Interventions: MM-151, MM-151 + irinotecan; Drug
Lead sponsor: Merrimack Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 4
States / cities: Aurora, Colorado • Lafayette, Indiana • Buffalo, New York + 1 more

Conditions: Non Small Cell Lung Cancer
Interventions: Patient Reported Outcome (PRO); Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 2
States / cities: Oceanside, California • Santa Rosa, California

Search by objective public record fields.

Treatment Patterns and Clinical Outcomes Among Patients With HR+/HER2- mBC Receiving Palbociclib Combination Therapy in the US Community Oncology Setting.

Lapatinib (GW572016) for Metastatic or Recurrent Squamous Cell Carcinoma Esophagus

Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer

Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer

RADIANT: Pre-op Radiation With Abemaciclib and Letrozole

Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)

Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients

A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent GBM

Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)

A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer

Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer

Gefitinib Followed By Surgery in Treating Women With Ductal Carcinoma In Situ of the Breast

Kidney Damage in Patients With Normal eGFR

A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Participants With ER+/HER2- Locally Advanced or Metastatic Breast Cancer

A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors

A Study of LY3164530 in Participants With Cancer

Study of Erbitux (Cetuximab) in Patients With Metastatic Colorectal Carcinoma

Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation

Effect of Panitumumab on the Pharmacokinetics of Irinotecan

Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer

A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain

A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment

TAURAS - T790 AURA ScreenFailure SOC Registry Study